Original Contributions |
From TNO-Prevention and Health, Gaubius Laboratory (F.d.B., W.L.H., L.C.v.V., S.W.A.K., L.M.H.), the Departments of Internal Medicine (F.d.B., L.C.v.V., S.W.A.K., A.H.M.S., L.M.H.) and Cardiology (L.M.H.), University Hospital, and the Department of Human Genetics (K.W.v.D., M.H.H.), Leiden University, Leiden, the Netherlands.
Correspondence to Dr L.M. Havekes, TNO-Prevention and Health, Gaubius Laboratory, Zernikedreef 9, 2333 CK Leiden, the Netherlands. E-mail LM.Havekes{at}PG.TNO.NL
AbstractThe binding of ß-VLDL
to heparan sulfate proteoglycans (HSPG) has been reported to be
stimulated by both apoE and lipoprotein lipase (LPL). In the
present study we investigated the effect of the isoform and the
amount of apoE per particle, as well as the role of LPL on the binding
of ß-VLDL to HSPG. Therefore, we isolated ß-VLDL from transgenic
mice, expressing either APOE*2(Arg158
Cys) or APOE*3-Leiden (E2-VLDL
and E3Leiden-VLDL, respectively), as well as from apoE-deficient mice
containing no apoE at all (Enull-VLDL). In the absence of LPL, the
binding affinity and maximal binding capacity of all ß-VLDL samples
for HSPG-coated microtiter plates was very low. Addition of LPL to this
cell-free system resulted in a 12- to 55-fold increase in the binding
affinity and a 7- to 15-fold increase in the maximal binding capacity
(Bmax). In the presence of LPL, the
association constant (Ka) tended to increase
in the order Enull-VLDL<E2-VLDL<E3Leiden-VLDL, whereas
Bmax increased in the reverse order:
E3Leiden-VLDL
E2-VLDL<Enull-VLDL. Addition of LPL resulted in a
marked stimulation of both Ka and
Bmax for binding of ß-VLDL samples to J774
cells similar to that found for the binding to HSPG-LPL complexes. Our
results indicate that both Ka and
Bmax for binding of ß-VLDL to HSPG are
increased more than 1 order of magnitude on addition of LPL. In
addition, for the binding of ß-VLDL to HSPG-LPL complexes, the
presence of apoE is not a prerequisite, but results in an increased
binding affinity, depending on the apoE isoform used.
Key Words: heparan sulfate proteoglycans lipoprotein lipase apoE ß-VLDL
This article has been cited by other articles:
![]() |
T. Koike, J. Liang, X. Wang, T. Ichikawa, M. Shiomi, H. Sun, T. Watanabe, G. Liu, and J. Fan Enhanced aortic atherosclerosis in transgenic Watanabe heritable hyperlipidemic rabbits expressing lipoprotein lipase Cardiovasc Res, February 1, 2005; 65(2): 524 - 534. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-y. Morita, M. Kawabe, A. Sakurai, K. Okuhira, A. Vertut-Doi, M. Nakano, and T. Handa Ceramide in Lipid Particles Enhances Heparan Sulfate Proteoglycan and Low Density Lipoprotein Receptor-related Protein-mediated Uptake by Macrophages J. Biol. Chem., June 4, 2004; 279(23): 24355 - 24361. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. C. Wilsie and R. A. Orlando The Low Density Lipoprotein Receptor-related Protein Complexes with Cell Surface Heparan Sulfate Proteoglycans to Regulate Proteoglycan-mediated Lipoprotein Catabolism J. Biol. Chem., April 25, 2003; 278(18): 15758 - 15764. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. E. Mullick, R. J. Deckelbaum, I. J. Goldberg, M. Al-Haideri, and J. C. Rutledge Apolipoprotein E and Lipoprotein Lipase Increase Triglyceride-Rich Particle Binding but Decrease Particle Penetration in Arterial Wall Arterioscler. Thromb. Vasc. Biol., December 1, 2002; 22(12): 2080 - 2085. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. C. N. Rensen, M. C. Jong, L. C. van Vark, H. van der Boom, W. L. Hendriks, T. J. C. van Berkel, E. A. L. Biessen, and L. M. Havekes Apolipoprotein E Is Resistant to Intracellular Degradation in Vitro and in Vivo. EVIDENCE FOR RETROENDOCYTOSIS J. Biol. Chem., March 17, 2000; 275(12): 8564 - 8571. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Paka, I. J. Goldberg, J. C. Obunike, S. Y. Choi, U. Saxena, I. D. Goldberg, and S. Pillarisetti Perlecan Mediates the Antiproliferative Effect of Apolipoprotein E on Smooth Muscle Cells. AN UNDERLYING MECHANISM FOR THE MODULATION OF SMOOTH MUSCLE CELL GROWTH? J. Biol. Chem., December 17, 1999; 274(51): 36403 - 36408. [Abstract] [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1999 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |